CYT-150 / Cytovia Therap, New York Stem Cell Foundation, CytoLynx Therap - LARVOL DELTA

Isleworth Healthcare Acquisition Corp. and Cytovia Therapeutics Announce Agreement for Business Combination to Create Publicly Listed Company Focused on Empowering Natural Killer Cell Therapeutics to Fight Cancer (PRNewswire) - "Cytovia plans to focus on multiple milestones, including: Filing the first two INDs for Flex-NK™ CYT-303 and iNK CYT-100; Initiating Phase I/II clinical trials to evaluate CYT-303 and CYT-100, alone and in combination, for the treatment of HCC; Obtaining and presenting initial clinical data for CYT-303 and CYT-100 in HCC; Filing INDs for CYT-150 and CYT-503 and initiating Phase I/II clinical trials."

Clinical data • IND • New P1/2 trial • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology • Solid Tumor

Cytovia and Cellectis Expand Their TALEN Gene-Edited iNK Partnership to Enable Broader Collaboration in China (GlobeNewswire) - "Cytovia Therapeutics...and Cellectis...announced today that they have expanded their collaboration of TALEN® gene-edited iPSC-derived NK and CAR-NK cells to include new CAR target and development in China by Cytovia’s joint venture entity, CytoLynx Therapeutics. The amended financial terms include an equity stake totaling $20 million in Cytovia stock as well as up to $805 million of development, regulatory, and sales milestones and single-digit royalty payments on the net sales of all partnered products commercialized by Cytovia."

Licensing / partnership • Oncology

Cytovia driving CAR NK manufacturing to Puerto Rico (BioProcess International) - "Cytovia Therapeutics will set up a facility in Aguadilla, Puerto Rico to support production of its off-the-shelf iPSC-derived CAR NK therapeutics. Cell therapy developer Cytovia has signed a long-term joint collaboration manufacturing and operations agreement with BioSciencesCorp to integrate Cytovia’s manufacturing processes within an existing 95,000 square-foot facility."

Commercial • Licensing / partnership • Oncology

Cytovia Therapeutics announces plans to initiate in 2021 Clinical Development of Universal iPSC NK Cell Therapy for Hematological and Solid Tumors (GlobeNewswire) - "Cytovia to present at RBC Capital Market Healthcare Conference on December 16, 2020. Cytovia Therapeutics...announced today that it plans to file with the FDA in 2021 an Investigational New Drug (IND) application and initiate clinical trials in hematological and solid tumors with its Universal iPSC NK cell therapy (U-iNK)...We are aiming to be, in 2021, the second company to initiate clinical trials with an iPSC NK product."

IND • New trial • Acute Myelogenous Leukemia • Hematological Malignancies • Oncology • Solid Tumor